Evidence map›Paper›PMID 33655803›Full record

ReviewJournal of dental research2021

Host Modulation and Treatment of Periodontal Disease.

M G Balta, E Papathanasiou, I J Blix, T E Van Dyke

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of dental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 8 pooled it
20.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 8 syntheses or guidelines pooled it, 183 citations in OpenAlex.

  1. The impact of periodontitis on physical fitness: a systematic review.Canadian journal of dental hygiene : CJDH = Journal canadien de l'hygiene dentaire : JCHD · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Article
  12. Article
  13. Review
  14. Type I interferon-induced CD169Journal of periodontology · 2026
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

M G BaltaThe CrossTalk Group, Institute of Oral Biology, University of Oslo, Oslo, Norway.ORCID 0000-0002-5831-1253
E PapathanasiouDepartment of Periodontology, School of Dental Medicine, Tufts University, Boston, MA, USA.ORCID 0000-0002-6425-4777
I J BlixThe CrossTalk Group, Institute of Oral Biology, University of Oslo, Oslo, Norway.
T E Van DykeCenter for Clinical and Translational Research, Forsyth Institute, Cambridge, MA, USA.ORCID 0000-0003-0856-3396
University of Oslo · NOHarvard University · USTufts University · US

Funding

Mechanisms of Resolvin E1 in Periodontal RegenerationR01DE025020 · NIDCR · ADA FORSYTH INSTITUTE, INC. · PI GUASTALDI, FERNANDO, VAN DYKE, THOMAS ELLIOTT · 2015 to 2023
$4.9M
Specialized Pro-resolving Mediators (SPMs) & scar tissue formation after cleft-lip surgical repairK08DE027119 · NIDCR · TUFTS UNIVERSITY BOSTON · PI PAPATHANASIOU, EVANGELOS · 2018 to 2023
$794k
NIDCR NIH HHS K08 DE027119NIDCR NIH HHS R01 DE025020
6 · The paper itself

Abstract

Periodontitis is the sixth-most prevalent disease in the world and the first cause for tooth loss in adults. With focus shifted to the inflammatory/immune response in the pathogenesis of periodontitis, there is a critical need to evaluate host modulatory agents. Synthetic and biological disease-modifying antirheumatic drugs are a cornerstone for the treatment of inflammatory diseases. Recent prospective cohort studies showed that synthetic disease-modifying antirheumatic drugs improved periodontal clinical parameters following nonsurgical periodontal treatment in patients with rheumatoid arthritis. Treatment with recombinant humanized monoclonal antibodies against CD20 (rituximab) and IL-6 receptor (tocilizumab), the latter also in clinical trials for the treatment of COVID-19 pneumonia, resulted in decreased periodontal inflammation and improved periodontal status. Studies on the effect of TNF-α inhibitors in patients with periodontitis yielded inconsistent results. Recent data suggest that probiotics provide anti-inflammatory clinical benefit, as do nutritional supplements, such as n-3 fatty acids, when combined with periodontal therapy. Probiotics reduce the production of proinflammatory cytokines/chemokines by suppressing NF-κB pathways and promote the accumulation of T regulatory cells. Statins, like aspirin, have been shown to exhibit anti-inflammatory and bone-preserving actions by upregulating production of Specialized Proresolving Mediators (SPMs). Currently, there is insufficient scientific support for the topical delivery of statins or bisphosphonates as adjuncts to periodontal therapy. Here, we present a critical review of the most recent host modulatory agents applied in humans and the key immune pathways that they target. Emerging evidence from novel drug candidates, including SPMs and complement inhibitors as previously studied in animal models and currently in human clinical trials, suggests future availability of adjunctive therapeutic strategies for the management of periodontitis.

Indexed as

COVID-19Periodontal DiseasesPeriodontitisAdultAnimalsHumansProspective StudiesSARS-CoV-2bone resorptioncytokinesimmune systeminflammationperiodontitistherapeutics

Identifiers

PMID33655803
PMCPMC8261853
OpenAlexW3134991047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.